Skip to main content
Premium Trial:

Request an Annual Quote

Consumer Genomics Startup Navigenics Makes Official Debut; Names Sue Siegel as Director

NEW YORK (GenomeWeb News) — Navigenics, a Bay Area company focused on using whole-genome scanning to identify an individuals’ genetic risks for certain diseases, today said it has made its official debut as a company.
The firm said it has also secured a Series B round of venture capital financing for an undisclosed amount, bringing its total funding to $25 million to date.
The company, which has named as a director former Affymetrix President Sue Siegel, said it will initially use saliva-based tests and genome scans to “help people understand their genetic predisposition to disease and arm them with the information about what actions to take.” Siegel is a partner with MDV-Mohr Davidow Ventures, which participated in the round.
Beside MDV-Mohr Davidow Ventures, Navigenics said participants in the financing included Kleiner Perkins Caufield & Byers and Sequoia Capital.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.